Back to resultsMK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Terminated
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
MK0767
Sponsored by
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Type 2 Diabetes with inadequate glycemic control
- Patient is on stable insulin therapy alone or with one oral antidiabetic agent
- Male or non-pregnant female 21 years or older
- Total daily dose of insulin must be less than or equal to 30 but not greater than or equal to 200 units/day
Exclusion Criteria:
- Have a history of type 1 diabetes mellitus
- History of ketoacidosis who are being treated with insulin
- Are taking 2 or more antidiabetic agents in combination with insulin
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00543816
Brief Title
MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2015
Overall Recruitment Status
Terminated
Study Start Date
August 2003 (undefined)
Primary Completion Date
November 2003 (Actual)
Study Completion Date
November 2003 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
This study will look to see if MK0767 works better than placebo in controlling blood sugar in patients with Type 2 Diabetes who are taking insulin but do not have adequate control of their blood sugar.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
MK0767
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 Diabetes with inadequate glycemic control
Patient is on stable insulin therapy alone or with one oral antidiabetic agent
Male or non-pregnant female 21 years or older
Total daily dose of insulin must be less than or equal to 30 but not greater than or equal to 200 units/day
Exclusion Criteria:
Have a history of type 1 diabetes mellitus
History of ketoacidosis who are being treated with insulin
Are taking 2 or more antidiabetic agents in combination with insulin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)
We'll reach out to this number within 24 hrs